Reckitt Benckiser Pharma, XenoPort Sign License Agreement
SLOUGH (Alliance News) - Reckitt Benckiser Group PLC's pharmaceuticals Inc unit will be granted exclusive worldwide rights for the development and commercialization of XenoPort Inc.'s clinical-stage oral product candidate arbaclofen placarbil for all indications. Arbaclofen placarbil is a Read More